temozolomide has been researched along with Digestive System Neoplasms in 4 studies
Digestive System Neoplasms: Tumors or cancer of the DIGESTIVE SYSTEM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although chemotherapy combining 5-fluorouracil (5FU)-dacarbazine (DTIC) or temozolomide (TEM)-capecitabine (CAP) is extensively used in patients with neuroendocrine tumors (NET), they were never compared." | 7.91 | Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. ( Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T, 2019) |
| "Although chemotherapy combining 5-fluorouracil (5FU)-dacarbazine (DTIC) or temozolomide (TEM)-capecitabine (CAP) is extensively used in patients with neuroendocrine tumors (NET), they were never compared." | 3.91 | Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. ( Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T, 2019) |
| "Temozolomide is a well-tolerated oral chemotherapy in patients with malignant DET, including those who have already received treatment." | 1.35 | Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. ( Couvelard, A; Faivre, S; Hammel, P; Hentic, O; Larroque, B; Lévy, P; Maire, F; Raymond, E; Ruszniewski, P; Yapur, L; Zappa, M, 2009) |
| "Temozolomide was studied using a continuous exposure at final concentrations from 0." | 1.30 | Activity of temozolomide against human tumor colony-forming units. ( Dugan, M; Gerson, SL; Izbicka, E; Raymond, E; Soda, H; Von Hoff, DD, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Mestier, L | 1 |
| Walter, T | 1 |
| Brixi, H | 1 |
| Evrard, C | 1 |
| Legoux, JL | 1 |
| de Boissieu, P | 1 |
| Hentic, O | 2 |
| Cros, J | 1 |
| Hammel, P | 2 |
| Tougeron, D | 1 |
| Lombard-Bohas, C | 1 |
| Rebours, V | 1 |
| Ruszniewski, P | 2 |
| Cadiot, G | 1 |
| Kesavan, M | 1 |
| Claringbold, PG | 1 |
| Turner, JH | 1 |
| Maire, F | 1 |
| Faivre, S | 1 |
| Yapur, L | 1 |
| Larroque, B | 1 |
| Couvelard, A | 1 |
| Zappa, M | 1 |
| Raymond, E | 2 |
| Lévy, P | 1 |
| Izbicka, E | 1 |
| Soda, H | 1 |
| Gerson, SL | 1 |
| Dugan, M | 1 |
| Von Hoff, DD | 1 |
1 trial available for temozolomide and Digestive System Neoplasms
| Article | Year |
|---|---|
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
3 other studies available for temozolomide and Digestive System Neoplasms
| Article | Year |
|---|---|
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Digesti | 2009 |
Activity of temozolomide against human tumor colony-forming units.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 1997 |